Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High volume haemodiafiltration in severe sepsis: pharmacokinetics of doripenem and piperacillin-tazobactam and inflammatory response
2011-000644-16Phase 4Completed
- Sponsor
- University of Tartu
- Start
- Mar 2011
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doripenem, piperacillin and tazobactam in sepsis, septic shock and acute kidney failure (AKF) (2 arms), sponsored by University of Tartu. Primary endpoint: Pharmacokinetic parameters of doripenem and piperacillin-tazobactam during high volume haemodiafiltration. Started Mar 2011; status: completed.
02
Drugs
03
Conditions
sepsisseptic shockacute kidney failure (AKF)
Beyond the preview
Go deeper on 2011-000644-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000644-16.